Stock Price
5.00
Daily Change
0.02 0.40%
Monthly
-10.55%
Yearly
-28.16%
Q4 Forecast
4.85

EPS Reference Time Actual Consensus Previous
2026-08-19 FY2026H1 AM 0.19 0.19



Peers Price Chg Day Year Date
Cspc Pharmaceutical 8.35 -0.01 -0.06% 5.83% Oct/23
Sino Biopharmaceutical 5.00 0.02 0.40% -28.16% Oct/23
Avita Medical 4.32 -0.04 -0.92% 240.16% Oct/23
Jiangsu Hengrui 47.02 1.02 2.22% -28.21% Oct/23
Akebia Therapeutics 0.57 0.005 0.84% -81.29% Oct/23
Tectonic Therapeutic 20.07 -1.02 -4.84% 17.03% Oct/23
Ionis Pharmaceuticals 42.93 -0.98 -2.23% -39.42% Oct/23
IQVIA Holdings 279.36 1.04 0.37% 26.68% Oct/23
Dianthus Therapeutics 76.78 -1.75 -2.23% 133.23% Oct/23
Moderna 200.10 -2.53 -1.25% 648.32% Oct/23

Indexes Price Day Year Date
HK50 23093 158.69 0.69% -11.72% Oct/23

Sino Biopharmaceutical Ltd traded at 5.00 this Friday October 23rd, increasing 0.02 or 0.40 percent since the previous trading session. Looking back, over the last four weeks, Sino Biopharmaceutical gained 10.55 percent. Over the last 12 months, its price fell by 28.16 percent. Looking ahead, we forecast Sino Biopharmaceutical Ltd to be priced at 4.85 by the end of this quarter and at 4.42 in one year, according to Trading Economics global macro models projections and analysts expectations.

Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.